Jazz Pharmaceuticals' Sunosi (solriamfetol) Receives FDA's Approval for the Treatment of Sleep Disorders
Shots:
- The approval is based on P-III TONES study assessing Sunosi (solriamfetol) vs PBO in 900 patients with excessive daytime sleepiness associated with narcolepsy or Obstructive Sleep Apnea (OSA)
- The P-III TONES study results: @12wks. improvement in PGIc scale (68-74% receiving 75mg & 78-90% receiving 150mg); improvement in wakefulness (assessed in the maintenance of wakefulness test)
- Sunosi (75mg & 150mg for narcolepsy) (37.5 mg- 75 mg &150 mg for OSA) is a NDRI inhibitor- developed and commercialized by Jazz (Ex. Asia) and has received FDA’s ODD for narcolepsy in the US
Click here to read full press release/ article | Ref: Jazz Pharmaceuticals | Image:Cronin Movers Group
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
